1-乙基-4-甲苯磺酰哌嗪 | 100800-51-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-乙基-4-甲苯磺酰哌嗪
• 英文名称: 1-ethyl-4-tosylpiperazine
• 英文别名: 1-ethyl-4-(4-methylphenyl)sulfonylpiperazine
• CAS: 100800-51-9
• 化学式: C₁₃H₂₀N₂O₂S
• mdl: MFCD01185476
• 分子量: 268.38
• InChiKey: XNPPSQLGKDCRRF-UHFFFAOYSA-N

物化性质

• 熔点：
  73 °C
• 沸点：
  196-198 °C(Press: 1.2 Torr)
• 密度：
  1.168±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  49
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-乙基哌嗪 、 对甲苯磺酰肼 在 叔丁基过氧化氢 、 碘化铵 作用下， 以 水 、 乙腈 为溶剂， 反应 16.0h， 以65%的产率得到1-乙基-4-甲苯磺酰哌嗪
  参考文献：
  名称：

  NH4I催化从芳基磺酰肼和胺类合成磺酰胺

  摘要：

  已经开发了一种新颖且有效的磺酰胺方法。使用TBHP作为氧化剂，使用NH 4 I（20 mol％）作为催化剂，芳基磺酰肼与胺反应生成磺酰胺，收率中等至良好。本文还讨论了产物形成的可能反应途径。

  DOI：

  10.1002/cjoc.201500796

文献信息

• NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY
  申请人：Cha Mi Young

  公开号：US20130116213A1

  公开（公告）日：2013-05-09

  The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.

  本发明涉及一种新型融合嘧啶衍生物，具有对酪氨酸激酶的抑制活性，以及一种药物组合物，其作为活性成分用于预防或治疗癌症、肿瘤、炎症性疾病、自身免疫疾病或免疫介导性疾病。
• Aromatic Compound
  申请人：Furukubo Shigeru

  公开号：US20090182142A1

  公开（公告）日：2009-07-16

  An aromatic compound represented by the following formula or a pharmaceutically acceptable salt thereof: , wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., G 1 , G 2 , G 3 , G 4 and G 5 are CH or N, X is —NH—, —O—, —CH 2 —, etc., Y is —CH 2 —, —CO—, —SO 2 —, etc., Z is a single bond, —CO—, —SO 2 —, —NH—, —O—, —S—, —CONH—, —SO 2 NH—, etc., R 2 is hydrogen, alkyl, alkoxy, halogen, etc., and R 3 is carbocyclic group, heterocyclic group, alkyl, etc., is useful as a controlling agent of the function of CCR4 useful for the treatment or therapy for bronchial asthma, atopic dermatitis, etc.

  下列的芳香族化合物或其药学上可接受的盐，其化学式如下：其中环A为杂环，环B为碳环、杂环等，G1、G2、G3、G4和G5为CH或N，X为—NH—、—O—、—CH2—等，Y为—CH2—、—CO—、—SO2—等，Z为单键、—CO—、—SO2—、—NH—、—O—、—S—、—CONH—、—SO2NH—等，R2为氢、烷基、烷氧基、卤素等，而R3为碳环基、杂环基、烷基等。该化合物对于控制CCR4功能的作用剂对于治疗或治疗支气管哮喘、特应性皮炎等疾病是有用的。
• 1-alkylsulfonyl-4-alkyl piperazines
  申请人：RHONE POULENC SA

  公开号：US02507408A1

  公开（公告）日：1950-05-09
• New Adamantane Phenylalkylamines with σ-Receptor Binding Affinity and Anticancer Activity, Associated with Putative Antagonism of Neuropathic Pain
  作者：Stefanos Riganas、Ioannis Papanastasiou、George B. Foscolos、Andrew Tsotinis、Guillaume Serin、Jean-François Mirjolet、Kostas Dimas、Vassilios N. Kourafalos、Andreas Eleutheriades、Vassilios I. Moutsos、Humaira Khan、Stavroula Georgakopoulou、Angeliki Zaniou、Margarita Prassa、Maria Theodoropoulou、Athanasios Mantelas、Stavroula Pondiki、Alexandre Vamvakides

  DOI：10.1021/jm3013008

  日期：2012.11.26

  The synthesis of:the adamantane phenylalkylamines 2a-d, 3a-c, and 4a-e is described These compounds exhibited significant antiproliferative activity, in vitro, against eight cancer cell lines tested The sigma(1), sigma(2). and Sodium channel binding affinities of compounds 2a, 3a, 4a, and 4c-e were investigated The most interesting analogue, 4a, exhibited significant in vivo anticancer profile on, pancreas, prostate, leukemia, and ovarian cancer cell line Xenografts.-together with,apoptosis and caspase-3 activation. Inhibition of the Cancer cells cycle at the sub-G1 level was also Obtained with 4a. Finally, encouraging results were observed With 4a in vivo on mice, suggesting putative antimetastatic and analgesic activities of this compound.
• Investigation of Antimicrobial Activities and Molecular Docking Studies of Synthesized Sulfonamide Compounds
  作者：G. Ozbey、E. S. Tanriverdi、B. F. Senkal、B. Korkmaz、S. Erkan、N. Bulut、F. Zigo、B. Otlu

  DOI：10.1007/s11094-023-03002-z

  日期：2023.12